In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Henrietta Lacks’ Harvested Cells: Is The Clock Ticking On Unjust Enrichment Claim?

Cells Were Harvested From Henrietta Lacks Without Her Knowledge Or Consent In 1951

Executive Summary

The descendants of Henrietta Lacks, a Black woman whose non-consensually harvested cervical cancer cells became the famous HeLa cell line, are suing Thermo Fisher Scientific. The family argue that Thermo Fisher’s ongoing profits from the various HeLa cell lines it commercializes and sells constitute unjust enrichment.

You may also be interested in...

Ultragenyx Faces Henrietta Lacks Suit Modeled On Action Against Thermo Fisher

While the unjust enrichment claim against Ultragenyx uses the same argument the estate of Henrietta Lacks employed against Thermo Fisher, resulting in a settlement earlier this month, one big difference between the cases is that Ultragenyx does not yet have a commercial product that relies on the HeLa cells.

‘The First Settlement’: Thermo Fisher Case Could Just Be Start Of The Road For Henrietta Lacks Suits

After settling for an undisclosed sum with Thermo Fisher, the estate of Henrietta Lacks signals it will initiate further lawsuits against defendants alleged to have unjustly profited from the use of HeLa cells.

J&J Cosmetic Talc Lawsuits Halted, $2Bn Trust Created, As Subsidiary Takes Liabilities Into Bankruptcy

Johnson & Johnson’s newly created subsidiary LTL Management LLC will take all cosmetic talc injury claims against the Johnson’s Baby Powder manufacturer into bankruptcy proceedings. J&J says the move is designed to ensure “equitable” resolution for all parties, while plaintiff’s attorneys have a decidedly different view on the matter.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts